Biotech has long recognized the benefits of using digital endpoints in clinical trials. Putting it into practice has been another matter. Our CMO, Diego Cadavid, spoke to BioCentury about how Verge is paving the way with a digital-first approach in our proof-of-concept study for ALS, including incorporating an Xbox sensor, to build a digital endpoint.
